PLoS ONE (Jan 2022)

Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases

  • Sofia A. Moll,
  • Mark G. J. P. Platenburg,
  • Anouk C. M. Platteel,
  • Adriane D. M. Vorselaars,
  • Montse Janssen Bonàs,
  • Raisa Kraaijvanger,
  • Claudia Roodenburg-Benschop,
  • Bob Meek,
  • Coline H. M. van Moorsel,
  • Jan C. Grutters

Journal volume & issue
Vol. 17, no. 11

Abstract

Read online

Background Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated. Methods 1463 ILD patients and 116 healthy subjects were screened for myositis antibodies with a line-blot assay on serum available at time of diagnosis. Additionally, bronchoalveolar lavage fluid (BALf) was analysed. Results A total of 394 patients demonstrated reactivity to at least one antibody, including anti-Ro52 (36.0%), anti-Mi-2β (17.3%) and anti-Jo-1 (10.9%). Anti-Jo-1 (OR 6.4; pConclusion In conclusion, novel associations of antibody Mi-2β with fibrotic ILD were found. Furthermore, serum anti-Mi-2β was associated with a histological UIP pattern and presence of anti-Mi-2β in BALf. Possibly, anti-Mi-2β could be implemented as a future diagnostic biomarker for fibrotic ILD.